Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Neurology · Paraneoplastic Brainstem Encephalitis

The Search for the Hidden Tumor

At a Glance

A negative CT scan does not rule out a small or regressed tumor in paraneoplastic brainstem encephalitis. Doctors may use antibody-guided scans, whole-body PET/CT, and repeat cancer screening over several years to find a hidden trigger.

Diagnosing paraneoplastic brainstem encephalitis is a complex process that involves two simultaneous goals: confirming the immune attack on the brainstem and hunting for a hidden (occult) tumor that may be triggering it. Because the neurological symptoms often appear months or even years before a tumor is large enough to see on standard scans, the diagnostic journey requires patience and specialized testing [1][2].

The 2021 Diagnostic Framework

Doctors use a standardized system called the PNS-Care Score to determine how likely it is that your symptoms are caused by a paraneoplastic syndrome. This score is an expert tool for estimating diagnostic confidence, not a stand-alone diagnostic test. It combines several pieces of evidence [3]:

  • The Phenotype: Your specific symptoms. Brainstem encephalitis is considered an “intermediate-risk” phenotype, meaning it is often—but not always—linked to cancer [4][3].
  • Antibody Type: Antibodies are categorized by their risk level. “High-risk” antibodies (like anti-Hu or anti-Ri) are associated with cancer in more than 70% of cases [3][5].
  • Cancer Status: Whether a tumor has been found that aligns with the antibody detected and the neurologic phenotype [3].

The score helps group patients into possible, probable, or definite categories, which guides the tumor search.

The Intensive Tumor Search

Standard imaging, such as a basic CT scan, is often not sensitive enough to find the very small tumors associated with brainstem encephalitis.

The Role of FDG-PET/CT

When conventional imaging is “unrevealing” (shows nothing), doctors may use whole-body FDG-PET/CT. This scan uses a small amount of radioactive sugar to identify cells that are unusually active. In research cohorts where standard scans found nothing, PET/CT has localized suspected malignancy in a subset of patients [6][7]. While highly sensitive, it can sometimes show “false positives”—areas of inflammation that are not cancer—so any “hot spots” must be carefully verified by your medical team [8][9]. PET/CT is a specialist-selected option tailored to your specific antibody and phenotype.

Specialized Scans

Depending on your antibodies, doctors may order more targeted tests:

  • Testicular Ultrasound: Essential for men with KLHL11 or Ma2 antibodies [10].
  • Mammography and Breast Ultrasound: Often prioritized for those with anti-Ri antibodies [11].

The Mystery of “Regressed” Tumors

In some cases, particularly with KLHL11 or Ma2 antibodies in men, the immune system may have been so successful at attacking the cancer that the original tumor has shrunk or disappeared. This is known as a regressed tumor [12][10].

Even if the primary tumor has regressed, the immune system may remain “locked” in an attack mode against the brainstem. In these cases, ultrasound may only show subtle signs like small calcifications (microlithiasis) or fibrous tissue [13][10]. These findings are nonspecific and do not prove that a tumor existed on their own; they require expert urologic and radiologic interpretation to help guide the overall assessment.

Why “Negative” is Not the End

A negative scan does not mean a tumor is not there; it may simply be too small to detect with current technology, or you may be a patient where an occult tumor is never found [14][15]. Because of this, medical guidelines emphasize the importance of serial screening for high-risk profiles.

While your doctor will create a plan tailored to your specific antibody and risk factors, patients with high-risk onconeural antibodies often undergo repeat imaging. For anti-Hu, surveillance might continue for up to 5 years [5][16]. Consistent monitoring is the best way to catch a tumor at its earliest, most treatable stage.

Common questions in this guide

What does the PNS-Care score mean for paraneoplastic brainstem encephalitis?
The PNS-Care score is an expert framework that combines the neurological pattern, the cancer risk associated with an antibody, and whether a matching tumor has been found. It estimates whether a paraneoplastic syndrome is possible, probable, or definite, but it is not a stand-alone diagnostic test.
What happens if a CT scan does not find a tumor?
A negative CT scan does not rule out a very small tumor or a cancer that is not yet visible. Depending on the antibody and neurological pattern, doctors may consider a whole-body FDG-PET/CT or other targeted scans, and some patients need repeated screening even when no tumor is initially found.
What can a hot spot on an FDG-PET/CT scan mean?
A hot spot is an area that uses more of the radioactive sugar given for the scan. Cancer can cause this appearance, but inflammation and other noncancerous conditions can also do so, so additional imaging, follow-up, or a biopsy may be needed to determine what it represents.
Which antibodies may lead to testicular or breast imaging?
Men with KLHL11 or Ma2 antibodies may be evaluated with a testicular ultrasound, while anti-Ri antibodies often lead doctors to prioritize mammography and breast ultrasound. The exact testing plan depends on the full antibody result, symptoms, and clinical assessment.
Can a tumor regress and still be linked to brainstem encephalitis?
Yes. In some people, especially men with KLHL11 or Ma2 antibodies, the immune system may shrink or eliminate the original tumor while the immune attack on the brainstem continues. Small calcifications or fibrous tissue on ultrasound can provide clues, but these findings are nonspecific and do not prove that a tumor was present.
How long might cancer screening continue after negative scans?
The schedule depends on the antibody, neurological pattern, and other risk factors. People with high-risk onconeural antibodies may need repeated imaging for several years; for anti-Hu antibodies, surveillance may continue for up to five years even if early scans are negative.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Paraneoplastic isolated brainstem encephalitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current 'PNS-Care Score,' and does it categorize my condition as 'definite' or 'probable' paraneoplastic syndrome?
  2. 2.Since my initial CT scans were clear, when should we schedule an FDG-PET/CT to look for a more hidden tumor?
  3. 3.If KLHL11 or Ma2 antibodies were found, has a urologist specifically looked for signs of a regressed tumor on my testicular ultrasound?
  4. 4.Based on my specific antibody risk profile, what is the recommended schedule for my follow-up cancer screenings?
  5. 5.If a PET scan shows a 'hot spot,' what are the next steps to confirm if it is actually cancer or just an area of inflammation?

References

References (16)
  1. 1

    Revisiting anti-Hu paraneoplastic autoimmunity: phenotypic characterization and cancer diagnosis.

    Villagrán-García M, Farina A, Muñiz-Castrillo S, et al.

    Brain communications 2023; (5(5)):fcad247 doi:10.1093/braincomms/fcad247.

    PMID: 37794924
  2. 2

    Kelch-like Protein 11 Antibodies in Seminoma-Associated Paraneoplastic Encephalitis.

    Mandel-Brehm C, Dubey D, Kryzer TJ, et al.

    The New England journal of medicine 2019; (381(1)):47-54 doi:10.1056/NEJMoa1816721.

    PMID: 31269365
  3. 3

    Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes.

    Graus F, Vogrig A, Muñiz-Castrillo S, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2021; (8(4)) doi:10.1212/NXI.0000000000001014.

    PMID: 34006622
  4. 4

    Clinical approach to neurological paraneoplastic syndromes.

    Anderson NE

    Internal medicine journal 2026; (56(8)):1314-1322 doi:10.1111/imj.70500.

    PMID: 42462243
  5. 5

    Clinical approach to diagnosis of paraneoplastic neurologic syndromes.

    Graus F

    Handbook of clinical neurology 2024; (200()):79-96 doi:10.1016/B978-0-12-823912-4.00007-4.

    PMID: 38494298
  6. 6

    F-Fluorodeoxyglucose positron-emission tomography for the investigation of malignancy in patients with suspected paraneoplastic neurologic syndromes and negative or indeterminate conventional imaging: a retrospective analysis of the Ontario PET Access Program, with systematic review and meta-analysis.

    Harlos C, Metser U, Poon R, et al.

    Current oncology (Toronto, Ont.) 2019; (26(4)):e458-e465 doi:10.3747/co.26.4583.

    PMID: 31548813
  7. 7

    Additional Value of [18F]FDG PET/CT in Detection of Suspected Malignancy in Patients with Paraneoplastic Neurological Syndromes Having Negative Results of Conventional Radiological Imaging.

    Opalińska M, Sowa-Staszczak A, Wężyk K, et al.

    Journal of clinical medicine 2022; (11(6)) doi:10.3390/jcm11061537.

    PMID: 35329862
  8. 8

    Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients.

    Kristensen SB, Hess S, Petersen H, Høilund-Carlsen PF

    European journal of nuclear medicine and molecular imaging 2015; (42(13)):2056-63 doi:10.1007/s00259-015-3126-2.

    PMID: 26194717
  9. 9

    Combination of positron emission tomography/computed tomography and chest thin-layer high-resolution computed tomography for evaluation of pulmonary nodules: Correlation with imaging features, maximum standardized uptake value, and pathology.

    Hou S, Lin X, Wang S, et al.

    Medicine 2018; (97(31)):e11640 doi:10.1097/MD.0000000000011640.

    PMID: 30075545
  10. 10

    Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis.

    Dubey D, Wilson MR, Clarkson B, et al.

    JAMA neurology 2020; (77(11)):1420-1429 doi:10.1001/jamaneurol.2020.2231.

    PMID: 32744608
  11. 11

    Breast cancer-associated opsoclonus-myoclonus syndrome: a case report.

    Kostoglou A, Vlastos D, Bakalis A, Ghosh D

    World journal of surgical oncology 2021; (19(1)):328 doi:10.1186/s12957-021-02436-7.

    PMID: 34781971
  12. 12

    Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis.

    Vogrig A, Péricart S, Pinto AL, et al.

    Brain communications 2021; (3(3)):fcab185 doi:10.1093/braincomms/fcab185.

    PMID: 34557666
  13. 13

    Ultrasound and Magnetic Resonance Imaging of Burned-Out Testicular Tumours: The Diagnostic Keys Based on 48 Cases.

    Desmousseaux T, Arama E, Maxwell F, et al.

    Cancers 2022; (14(16)) doi:10.3390/cancers14164013.

    PMID: 36011006
  14. 14

    Accuracy of FDG-PET/CT and paraneoplastic antibodies in diagnosing cancer in paraneoplastic neurological syndromes.

    Vatankulu B, Yilmaz Aksoy S, Asa S, et al.

    Revista espanola de medicina nuclear e imagen molecular 2016; (35(1)):17-21.

    PMID: 26260889
  15. 15

    SOX-1 antibodies positive Lambert-Eaton myasthenic syndrome with occult small cell lung cancer: A case report.

    Zhao L, He H, Han W, et al.

    The clinical respiratory journal 2024; (18(3)):e13740 doi:10.1111/crj.13740.

    PMID: 38497229
  16. 16

    [Clinical characteristics of "classical" and "non-classical" paraneoplastic neurological syndrome].

    Lyu XY, Wang GP, Tang QQ, et al.

    Zhonghua yi xue za zhi 2021; (101(9)):615-619 doi:10.3760/cma.j.cn112137-20200616-01870.

    PMID: 33685041

This page explains how clinicians search for an occult tumor in paraneoplastic brainstem encephalitis for informational purposes only and does not constitute medical advice. Your neurologist and oncology team should tailor testing and follow-up to your situation.